Ellicott City, M.D. – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year partnership with Laboratory Corporation of America® Holdings (LabCorp®) (LH: NYSE). Under the agreement, Covance Drug Development (Covance) will participate as a Global Impact Partner (GIP), a relationship designed to facilitate critical dialogue between industry stakeholders and clinical research sites.
"Covance's commitment to partner with SCRS as a GIP demonstrates that establishing positive site relationships is a high priority for them," commented Christine Pierre, SCRS President. "SCRS' GIPs are focused on acknowledging the realities that today's sites face, and actively addressing their challenges. SCRS is proud to welcome Covance as our newest Global Impact Partner."
"Covance is committed to serving the clinical research community as a strong scientific partner in order to speed the development of innovative medicines that meet today's global healthcare needs," said Jill Johnston, Global Vice President, Site Activation, Informatics and Optimization, Covance. "Our work with SCRS will help us better understand the needs of our clinical research partners and ultimately improve service to our pharmaceutical and biotechnology clients."
As a GIP, Covance will participate on the SCRS Global Impact Board at an executive level, and work in tandem with SCRS' Leadership Council in the development and execution of strategic initiatives for SCRS.
####
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 2,400 research sites, including 30,000 research professionals in 42 countries. SCRS' mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites, as well as companies that sponsor or support the work conducted at clinical research sites, will benefit from membership and partnership. Visit MySCRS.org.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500 company, is the world's leading healthcare diagnostics company, providing comprehensive clinical laboratory services through LabCorp Diagnostics, and end-to-end drug development support through Covance Drug Development. LabCorp is a pioneer in commercializing new diagnostic technologies and is improving people's health by delivering the combination of world-class diagnostics, drug development and knowledge services. With combined revenue proforma for the Covance acquisition in excess of $8.5 billion in 2014 and more than 48,000 employees in over 60 countries, LabCorp offers innovative solutions to healthcare stakeholders. LabCorp clients include physicians, patients and consumers, biopharmaceutical companies, government agencies, managed care organizations, hospitals, and clinical labs. To learn more about Covance Drug Development, visit www.covance.com. To learn more about LabCorp and LabCorp Diagnostics, visit www.labcorp.com.